Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHP 681

Next Previous
Drug Profile

SHP 681

Alternative Names: GLP-2 Analog-Fc Fusion; SHP-681; TAK-681

Latest Information Update: 28 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Recombinant fusion proteins
  • Mechanism of Action Glucagon-like peptide 2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Short bowel syndrome

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for phase-I development in Short-bowel-syndrome(In volunteers) in USA (SC, Injection)
  • 06 Jan 2020 Takeda completes a phase I trial in Short bowel syndrome (In volunteers) in USA (SC) (NCT03859323)
  • 26 Mar 2019 Phase-I clinical trials in Short bowel syndrome (In volunteers) in USA (SC) (NCT03859323)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top